Articles

John Donne, a 16th century poet, wrote a work called “Death, be not proud” (also known as “Holy Sonnet 10”) about death. One line in particular always catches my attention: “….And soonest our best men with thee do go.” Donne stated the obvious: everyone dies, and for many, death comes too soon. Read More ›

In women with metastatic breast can­cer, less frequent dosing of zoledronic acid (ZA) may be as protective as the standard monthly infusion, according to 2 studies presented at the 2012 Annual Meeting of the American So­ciety of Clinical Oncology (ASCO). Read More ›

According to an analysis of the Eastern Cooperative Oncology Group trial ECOG-E1199 by Schneider and colleagues, the development of grade 2 to 4 peripheral neuropathy in patients with operable breast cancer who received taxanes does not appear to affect clinical outcome. Read More ›

Adverse events (AEs) related to chemotherapy for metastatic breast cancer (MBC) create a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said Sara A. Hurvitz, MD, of the University of California Los Angeles, who presented an economic analysis at the 2012 Annual Meeting of the American Society of Clinical Oncology. Read More ›

A “group visit” model, led by nurse practitioners, is a feasible and highly satisfactory means of following breast cancer survivors, according to 2 oncology nurse re­searchers from the Duke Cancer Cen­ter’s program. Read More ›

The American Society of Clin­ical Oncology 2012 Breast Can­cer Symposium, held September 13-15 in San Francisco, California, offered all members of the cancer team an upfront view of new data and an opportunity for one-on-one interaction with experts in the field. The following are a few re­search items of interest to oncology nurses. Read More ›

The mission of the John Theurer Cancer Center is to deliver extraordinary care that is multidisciplinary, personalized, innovative, and at the appropriate cost with superior outcomes to the most satisfied patients. Read More ›

Oncology experts from all over the globe arrived in Vienna, Austria, to attend the Euro­pean Society for Medical Oncology (ESMO) 2012 Congress. Attendance broke all records, with 16,394 delegates, many of them from outside of Europe: 1116 from the United States, 539 from Japan, 479 from China, 292 from Argentina, and 258 from Brazil. Read More ›

In a phase 3 head-to-head comparison trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib proved more effective than standard chemo­therapy with pemetrexed or docetaxel as a second-line treatment for non–small cell lung cancer (NSCLC) patients with the ALK genetic abnormality. Read More ›

Early breast cancer patients who gain weight after treatment are at increased risk for breast cancer recurrence, according to an Italian study presented at the European Society for Medical Oncology 2012 Congress, held in Vienna, Austria. Read More ›